Jonathan E Constance
Overview
Explore the profile of Jonathan E Constance including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
34
Citations
291
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yellepeddi V, Race J, McFarland M, Constance J, Fanaeian E, Murphy N
Int J Clin Pharmacol Ther
. 2024 Apr;
62(6):267-277.
PMID: 38577753
Objectives: To describe the efficacy of atropine in controlling salivary flow in patients with sialorrhea or drooling. Materials And Methods: We included randomized controlled studies, quasi-randomized trials, case reports, clinical...
2.
Constance J, McFarland M, Casucci T, Deininger M, Enioutina E, Job K, et al.
JMIR Res Protoc
. 2023 May;
12:e38167.
PMID: 37213193
Background: Numerous reports contend opioids can augment or inhibit malignancy. At present, there is no consensus on the risk or benefit posed by opioids on malignancy or chemotherapeutic activity. Distinguishing...
3.
Yellepeddi V, Parashar K, Dean S, Watt K, Constance J, Baker O
Clin Transl Sci
. 2020 Nov;
14(2):683-691.
PMID: 33202089
Sjögren's syndrome (SS) is an autoimmune disease with no effective treatment options. Resolvin D1 (RvD1) belongs to a class of lipid-based specialized pro-resolving mediators that showed efficacy in preclinical models...
4.
Rower J, King A, Wilkins D, Wilkes J, Yellepeddi V, Maese L, et al.
J Adolesc Young Adult Oncol
. 2020 Jul;
10(2):175-184.
PMID: 32678694
The therapeutic utility of in cancer is a topic of intense interest. Dronabinol is synthetic Δ-tetrahydrocannabinol (THC), the primary psychoactive component of , and is approved for treating refractory chemotherapy-induced...
5.
Biltaji E, Enioutina E, Yellepeddi V, Rower J, Sherwin C, Ward R, et al.
Leuk Lymphoma
. 2020 Apr;
61(8):1920-1931.
PMID: 32264729
Pharmacokinetic (PK) conflicts can arise between supportive care medications (SCM) and chemotherapy in children with hematologic malignancy (HM). In this retrospective study, medical records for children (28 days-18 years) diagnosed...
6.
Constance J, Campbell S, Somani A, Yellepeddi V, Owens K, Sherwin C
Expert Opin Drug Metab Toxicol
. 2017 May;
13(7):715-724.
PMID: 28490206
Advancing appropriate and adequate analgesic pharmacotherapy in pediatric patients with cancer is an area of clinical need. Few studies have been performed to evaluate the selection of an analgesic and...
7.
Job K, Kiang T, Constance J, Sherwin C, Enioutina E
Expert Rev Clin Pharmacol
. 2016 Sep;
9(12):1597-1609.
PMID: 27644147
Similar to other nations North American people used herbs for thousands of years to treat diseases and purify their spirits. By the middle of the 1900s, evidence-based conventional medicine received...
8.
Job K, Olson J, Stockmann C, Constance J, Enioutina E, Rower J, et al.
Expert Rev Anti Infect Ther
. 2016 Jun;
14(8):731-46.
PMID: 27355512
Introduction: Voriconazole is a broad-spectrum antifungal agent commonly used to treat invasive fungal infections (IFI), including aspergillosis, candidiasis, Scedosporium infection, and Fusarium infection. IFI often occur in immunocompromised patients, leading...
9.
Stockmann C, Sammons H, Starkey E, Constance J, Sherwin C
Ther Drug Monit
. 2016 May;
38(3):419-20.
PMID: 27172382
No abstract available.
10.
Enioutina E, Constance J, Stockmann C, Linakis M, Yu T, Rower J, et al.
Expert Opin Drug Metab Toxicol
. 2015 Nov;
11(12):1861-78.
PMID: 26535960
Introduction: Neonatal patients, because of the inability of their immune system to properly respond to microbial challenge, are highly susceptible to viral infections. Immunoglobulins, monoclonal antibody and antiviral drugs are...